Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This investigation shows that resistin promotes VEGF-A expression in human osteosarcoma cells and activates the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 signaling pathways, while ERK, JNK, and p38 inhibitors or their small interfering RNAs (siRNAs) inhibit resistin-induced VEGF-A expression as well as endothelial progenitor cell (EPC) migration and tube formation.
|
31719210 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLEFMA Activates the Extrinsic and Intrinsic Apoptotic Processes through JNK1/2 and p38 Pathways in Human Osteosarcoma Cells.
|
31505816 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[Corrigendum] All-trans retinoic acid restored the osteogenic ability of BMP9 in osteosarcoma through the p38 MAPK pathway.
|
31268160 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicated that artemisinin could inhibit angiogenesis by regulating the p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.
|
30746754 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-338-3p/AHSA1 can serve as a potential therapeutic target for OS therapy.
|
29618948 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All these data supported the hypothesis that the anticancer effect of salvianolic acid B includes the suppression of cell proliferation and induces apoptosis in MG63 cells, and that p38 is important in the anticancer effect of salvianolic acid B on osteosarcoma cells due to the direct regulation of ROS generation.
|
29434992 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrates that VACP1 potently suppressed cell proliferation and induced the cell apoptosis of OS cells by inducing the activation of the p38 MAPK and JNK signaling pathways, suggesting that VACP1 is a promising agent for OS therapy.
|
29607921 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The combination of oleandrin with cisplatin exerts a synergistic antitumor effect in osteosarcoma, which relates to the activation of the p38 MAPK pathway.
|
30267330 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that simvastatin induces apoptosis in osteosarcoma cells via activation of AMPK and p38 MAPK, and that, in combination with other approaches, it holds therapeutic potential for osteosarcoma.
|
27799356 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid restored the osteogenic ability of BMP9 in osteosarcoma through the p38 MAPK pathway.
|
28350136 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The function of AHSA1 in osteosarcoma (OS) has not been reported yet.
|
26796264 |
2016 |
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The results demonstrated that NOV increased the phosphorylation of p38 and c-Jun N-terminal kinase (JNK) mitogen-actived protein kinases (MAPKs) in osteosarcoma cell lines.
|
26238193 |
2015 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An inhibitor of MEK1 activation (PD98059) that prevents downstream extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and a specific inhibitor of p38 were also used as mitogen activated protein kinase-targeting therapy is being investigated as a treatment modality for osteosarcoma.
|
23262982 |
2013 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, p38 MAPK inhibitor abrogated GA-induced growth inhibition of osteosarcoma cells, whereas JNK or ERK1/2 inhibitors sensitized osteosarcoma cells to GA-induced growth inhibition.
|
22849560 |
2012 |
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, it was observed that the phlorotannins inhibited phosphorylation of JNK and p38 MAPK in human osteosarcoma cell.
|
19330880 |
2009 |